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t(5;12)(q31;p13) G- banding - Courtesy Melanie Zenger and 
Claudia Haferlach. 
Clinics and pathology 
Disease 
The t(5;12)(q31;p13) translocation involving ETV6 
(12p13) and ACSL6 (5q31) was found in a patient with 
refractory anemia with excess blasts (RAEB) with 
basophilia, a patient with acute myelogenous leukemia 
(AML) with eosinophilia, and a patient with acute 
eosinophilic leukemia (AEL). 
Phenotype / cell stem origin 
Myeloid lineage. 
Epidemiology 
To date, one case with myelodysplastic syndrome 
(RAEB), one case with AML, one case with AEL, one 
case with atypical CML, and 2 cases with 
Polycythemia Vera (PV). 
The t(5;12)(q31;p13) is a recurrent translocation in 
myeloid malignancies (at least 23 cases reported). 
Prognosis 





May be not easy to detect. 
Cytogenetics molecular 
The translocation can be detected by FISH with ETV6 
probes. The ETV6 gene is rearranged, and the 
breakpoint is between exon 1 and exon 2 in all cases 
reported. 
Additional anomalies 
Disruption of the second ETV6 allele by t(12;19) was 
detected in the AML case by FISH analysis. 
Variants 
No variants. 
Genes involved and Proteins 
ETV6 (ETS Variant gene 6) 
Location: 12p13 
Note: The gene is known to be involved in a large 
number of chromosomal rearrangements associated 
with leukemia and congenital fibrosarcoma. 
DNA / RNA 
9 exons; alternate splicing 
Protein 
The gene encodes an ETS family transcription factor; 
the product of this gene contains a N-terminal pointed 
(PNT) domain that is involved in the protein-protein 
interactions, and a C-terminal ETS DNA-binding 
domain; wide expression; nuclear localization. 
ACSL6 (Acyl-CoA Synthetase Long-
chain family member 6) 
Location: 5q31 
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Note: None of the resulting chimeric transcripts, except 
for the ACSL6/ETV6 transcript in the RAEB case, led 
to a fusion protein. 
DNA / RNA 
57,74 kb, 21 exons; alternate splicing. 
Protein 
Two splicing isoforms, a long and a short. The gene 
encodes an AMP binding enzyme; plays an important 
role in fatty acid metabolism in brain, responsible for 
activation of long-chain fatty acids in erythrocytes. 
Wide expression, expression low at earlier stages of 
erythroid development but very high in reticulocytes. 




A novel human gene, called ACS2 (acyl-CoA 
synthetase-2), was identified as an ETV6 fusion partner 
in a recurrent t(5;12)(q31;p13) translocation. Northern 
blot analysis detected high levels of ACS2 expression 
in brain, fetal liver, and bone marrow, and the gene was 
found to be highly conserved in man and rat. The 
ETV6/ACSL6 fusion transcripts showed an out-frame 
fusion of exon 1 of ETV6 to exon 1 of ACSL6 in the 
AEL patient, an out-frame fusion of exon 1 of ETV6 to 
exon 11 of ACSL6 in the AML patient, and a short in-
frame fusion of exon 1 of ETV6 to the 3-prime 
untranslated region of ACSL6 in the patient with 
RAEB. Reciprocal ACSL6/ETV6 transcripts were 
identified in 2 of the cases. FISH with ETV6 cosmids  
on 12p13, and BACs and PIs on 5q31, demonstrated 
that the 5q31 breakpoints of the AML and AEL cases 
involved the 5-prime portion of the ACSL6 gene, and 
that the 5q31 breakpoint of the RAEB case involved 
the 3-prime portion of the ACSL6 gene. None of the 
resulting chimeric transcripts except for the 
ACSL6/ETV6 transcript in the RAEB case led to a 
fusion protein. 
A case with a CML and a t(5;12)(q31;p13) was 
characterized, and 3 different ETV6/ACSL6 transcripts 
were detected. Moreover, as a consequence of the 
translocation IL-3/CSF2, located at 5q31, was 
ectopically expressed in the leukemic cells. 
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